Lions Outback Vision, Lions Eye Institute, Nedlands, WA 6009, Australia
Rural Remote Health. 2021 Aug;21(3):6001. doi: 10.22605/RRH6001. Epub 2021 Aug 11.
Regular intravitreal injections are an important treatment for significant vision impairment caused by diabetic macular oedema. Barriers to intravitreal treatment for rural Australian patients include travel time to appointments, especially as patients face a high volume of other medical appointments for their diabetes and related co-morbidities. This audit addresses intravitreal injection compliance by identifying patients lost to follow up in north-western Western Australia.
A retrospective audit of all injections was performed in the Pilbara and Kimberley between January and December 2018. Outcome measures included total injections, number of injection patients, rates of patients lost to follow-up by region, Aboriginal and Torres Strait Islander status and diagnosis. The audit was extended to include the first 6 months of 2019 to ensure further treatment plan timeframes had lapsed.
A total of 140 patients received injections, resulting in 346 injections. Ten patients were excluded due to relocation to another region and three patients were deceased. Seventeen patients were lost to follow-up (12.1%). Of those lost to follow-up, 14.3% were in the Pilbara region and 10% in the Kimberley region. Similar rates with respect to Indigenous status with 12.6% identifying as Aboriginal and 11.4% not. 15.8% were treated for diabetic macular oedema and 3.8% for age-related macular degeneration.
The logistics of providing appropriate intravitreal therapy, including scheduling timely visits and working in hospital and community-controlled settings, requires a specific focus on those needing intravitreal treatment. The study highlights the importance of coordination and systems to enable patients to receive injections in remote settings. Further analysis of optimal patient management plans for appropriate frequency and treatment outcomes is required.
对于由糖尿病性黄斑水肿引起的严重视力损害,定期玻璃体内注射是一种重要的治疗方法。对于澳大利亚农村地区的患者,玻璃体内治疗的障碍包括预约的旅行时间,尤其是因为患者需要大量的其他医疗预约来治疗糖尿病及其相关的合并症。这项审计通过确定在澳大利亚西北部失去随访的患者,来解决玻璃体内注射的依从性问题。
对 2018 年 1 月至 12 月在皮尔巴拉和金伯利进行的所有注射进行了回顾性审计。结果测量包括总注射次数、注射患者人数、按地区、原住民和托雷斯海峡岛民身份和诊断分类的失访率。审计范围扩大到 2019 年的前 6 个月,以确保进一步的治疗计划时间框架已经过期。
共有 140 名患者接受了注射,共进行了 346 次注射。由于搬迁到另一个地区,有 10 名患者被排除在外,有 3 名患者死亡。有 17 名患者失访(12.1%)。在失访者中,14.3%在皮尔巴拉地区,10%在金伯利地区。原住民身份的比例相似,12.6%的人认为自己是原住民,11.4%的人不是。15.8%的患者因糖尿病性黄斑水肿接受治疗,3.8%的患者因年龄相关性黄斑变性接受治疗。
提供适当的玻璃体内治疗的后勤工作,包括安排及时的就诊和在医院和社区控制的环境中工作,需要特别关注需要玻璃体内治疗的患者。该研究强调了协调和系统的重要性,以确保患者能够在偏远地区接受注射。需要进一步分析适当频率和治疗结果的最佳患者管理计划。